Work

The Impact of Lipid-lowering Therapies on the Management of Dyslipidemia and the Prevention of Cardiovascular Events

Year: 2024

Type: article

Abstract: Lipid-lowering therapies, such as PCSK9 inhibitors and bempedoic acid, are essential in the treatment of dyslipidemia, especially for patients who do not reach their LDL-C targets with statins.PCSK9 inhibitors can reduce LDL-C levels by up to 60% and have shown efficacy in preventing cardiovascular events in high-risk populations.However, their high cost limits access, generating debate about cost-effectiveness, especially in developing countries.Bempedoic acid offers an alternative for those who cannot tolerate statins, but its efficacy in cardiovascular events still needs more data.Long-term safety and affordability are key concerns as these therapies evolve.

Source: International Journal of Health Science

DOI: 10.22533/at.ed.1594952423105

Authors: Jhony Lucas Inácio de Almeida, Gabriel Nogueira Zuntini, Giovana Elisa Rosa Galiassi, Mikaella Dal Piva, Nicolli Zamo Ortolan

Institution: Universidade de Cuiabá

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4403856001